Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | KHK | P50053 | 6/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23588991 | 1.00 | HTR6 (0.46) | HTR6KHKCHRM2CHRM1CHRM3 | |
| SCHEMBL16365472 | 1.00 | HTR6 (0.46) | HTR6KHKCHRM2CHRM1CHRM3 | |
| SCHEMBL31208709 | 0.89 | HTR6 (0.39) | HTR6KHKCCNT1CDK9 | |
| SCHEMBL233141 | 0.88 | CHRM2 (0.37) | HTR6KHKCHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL18693791 | 0.86 | CHRM2 (0.36) | HTR6KHKCHRM2CHRM1CHRM3 | |
| SCHEMBL21570134 | 0.86 | HTR6 (0.36) | HTR6KHKCCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL2476511 | 0.84 | HTR6 (0.35) | HTR6CCNT1CDK9 | |
| SCHEMBL31209187 | 0.82 | HTR6 (0.38) | HTR6KHK | |
| SCHEMBL5225386 | 0.78 | HTR6 (0.50) | HTR6KHK | |
| SCHEMBL21816613 | 0.77 | IRAK4 (0.36) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| WO-2014202458-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR6 4845/4885KHK 2468/4885CHRM2 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.